A 38-year-old woman from rural India undergoes cervical cancer screening. Her Pap smear shows atypical squamous cells of undetermined significance (ASC-US), and HPV testing is positive for high-risk HPV 16. Which management approach best distinguishes her risk profile from a woman with ASC-US and negative HPV testing?

Explanation

## Risk Stratification in ASC-US: Role of HPV Testing ### Clinical Context **Key Point:** ASC-US is the most common abnormal cytology finding, and HPV testing is the gold standard for risk stratification. HPV-positive ASC-US carries significantly higher risk of underlying CIN 2/3 or cancer, whereas HPV-negative ASC-US has very low risk (< 1% of CIN 2/3). ### Management Algorithm for ASC-US ```mermaid flowchart TD A[ASC-US on Pap smear]:::outcome --> B{HPV testing result?}:::decision B -->|HPV positive| C[Colposcopy with biopsy]:::action B -->|HPV negative| D[Routine screening in 3 years]:::action C --> E[Assess for CIN 2/3 or cancer]:::outcome D --> F[Low risk - continue standard screening]:::outcome ``` ### Risk Stratification by HPV Status | Finding | HPV-Positive ASC-US | HPV-Negative ASC-US | |---------|-------------------|--------------------| | **Risk of CIN 2/3** | 20–30% | < 1% | | **Risk of cancer** | 5–10% | < 0.5% | | **Recommended action** | Immediate colposcopy | Routine screening in 3 years | | **Rationale** | High-risk HPV is necessary for progression | Absence of high-risk HPV indicates very low malignant potential | ### Why HPV Testing Distinguishes Risk **High-Yield:** High-risk HPV (types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) is a necessary precursor for cervical carcinogenesis. HPV-negative ASC-US is almost always benign (inflammation, metaplasia, reactive changes), whereas HPV-positive ASC-US has substantial risk of underlying dysplasia. **Mnemonic:** **HPV-ASC Rule** — HPV-positive ASC-US → colposcopy now; HPV-negative ASC-US → reassure and rescreen in 3 years. ### Clinical Pearl **Key Point:** In resource-limited settings (common in India), HPV testing on ASC-US samples is cost-effective because it avoids unnecessary colposcopy in the majority of women (60–70% are HPV-negative) while ensuring that high-risk women are not missed. ### Guideline Basis This approach follows **ASCCP 2019 guidelines** and is endorsed by WHO for cervical cancer prevention in low-resource settings. HPV testing has replaced reflex cytology as the preferred triage method for ASC-US. [cite:Park 26e Ch 3]